idirect_jubilantpharmova_q3fy26 Post navigation Previous Previous post: Jubilant Pharmova has an aspirational target for FY30 of doubling of overall revenues. Buy for target price of ₹1310 (41% upside): ICICI Direct Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Current ye@r * Leave this field empty